{"id":"sklb1028","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3678958","moleculeType":"Small molecule","molecularWeight":"443.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SKLB1028 inhibits receptor tyrosine kinases and intracellular signaling pathways critical for tumor growth. The drug is designed to block multiple kinase targets simultaneously, potentially providing broader anti-cancer activity. It has been developed primarily for solid tumors in early clinical development.","oneSentence":"SKLB1028 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and survival.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:34:52.400Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT05445154","phase":"PHASE1, PHASE2","title":"SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-08-31","conditions":"Newly Diagnosed Acute Myeloid Leukemia (AML)","enrollment":58},{"nctId":"NCT05369858","phase":"PHASE1","title":"A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-08-06","conditions":"Healthy Male Subjects","enrollment":6},{"nctId":"NCT05109663","phase":"PHASE1","title":"A Dose Escalation and Food Effect Study of SKLB1028 in Healthy Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-04-14","conditions":"Healthy Subjects","enrollment":26},{"nctId":"NCT04716114","phase":"PHASE3","title":"A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-03-24","conditions":"Acute Myeloid Leukemia (AML)","enrollment":315},{"nctId":"NCT05072522","phase":"PHASE1","title":"A Study of SKLB1028 in Patients With Advanced Solid Tumor","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-10","conditions":"Advanced Solid Tumors","enrollment":98},{"nctId":"NCT05070195","phase":"PHASE1","title":"A Study to Investigate the Drug-drug Interactions (DDIs) Between SKLB1028 and Midazolam in Healthy Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-06-07","conditions":"Healthy Subjects","enrollment":14},{"nctId":"NCT05069870","phase":"PHASE1","title":"A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy Subjects","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-06-07","conditions":"Healthy Subjects","enrollment":42},{"nctId":"NCT04015024","phase":"PHASE2","title":"A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2019-07","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT02859948","phase":"PHASE1","title":"A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2016-05","conditions":"Acute Myeloid Leukemia","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SKLB1028","genericName":"SKLB1028","companyName":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","companyId":"cspc-zhongqi-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SKLB1028 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and survival. Used for Solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}